Founded in 2024 by MPM BioImpact, K2 Therapeutics builds a diversified pipeline by sourcing therapeutic assets worldwide and advancing them through disciplined drug development. The company’s portfolio includes eight therapeutic programs spanning multiple modalities, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), with programs ranging from preclinical to clinical stage. K2 completed a $50 million seed financing from MPM BioImpact that has supported portfolio expansion and program advancement. Leadership changes accompanying the financing include the appointment of Dr. Ying Huang as CEO and Frank Neumann, M.D., serving as Chief Medical Officer. K2 plans to continue expanding its portfolio through disciplined asset acquisition, strategic capital deployment and focused development execution. The company presents operations tied to Boston and Singapore.

Total raised

$50M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2026